Illumina, Inc. is an American company that develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function. Using its technologies, the Company provides a line of products and services that serve the sequencing, genotyping and gene expression markets. Illumina's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations and biotechnology companies.

TypePublic
HQSan Diego, US
Founded1998
Size (employees)6,200 (est)+13%
Websiteillumina.com
Illumina was founded in 1998 and is headquartered in San Diego, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Illumina Office Locations

Illumina has offices in Singapore, San Diego, Madison, San Francisco and in 11 other locations
San Diego, US (HQ)
5200 Illumina Way
Madison, US
200 5602 Research Park Blvd
Redwood City, US
800 Saginaw Dr
San Francisco, US
210 499 Illinois St
Santa Clara, US
210 451 El Camino Real
Scoresby, AU
1 International Ct
Show all (15)
Report incorrect company information

Illumina Financials and Metrics

Illumina Revenue

Illumina's revenue was reported to be $2.40 b in FY, 2017
USD

Revenue (Q2, 2019)

1.6b

Gross profit (Q2, 2019)

1.1b

Gross profit margin (Q2, 2019), %

69%

Net income (Q2, 2019)

397.0m

EBIT (Q2, 2019)

445.0m

Market capitalization (18-Oct-2018)

47.3b

Closing stock price (18-Oct-2018)

321.5

Cash (1-Jul-2018)

1.3b

EV

46.6b
Illumina's current market capitalization is $47.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

1.4b1.9b2.2b2.4b2.4b

Revenue growth, %

31%19%8%

Cost of goods sold

670.5m731.9m731.9m

Gross profit

1.5b1.7b1.7b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017Q1, 2017Q2, 2017Q1, 2019Q2, 2019

Revenue

356.8m420.8m447.6m480.6m538.6m539.4m550.3m607.1m571.8m600.1m714.0m598.0m662.0m782.0m1.6b

Cost of goods sold

146.9m142.5m147.0m146.7m163.5m163.0m162.7m181.0m174.7m176.3m232.0m230.0m228.0m244.0m499.0m

Gross profit

209.9m278.3m300.5m333.9m375.0m376.4m387.5m426.2m397.1m423.8m482.0m368.0m434.0m538.0m1.1b

Gross profit Margin, %

59%66%67%69%70%70%70%70%69%71%68%62%66%69%69%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

711.6m636.2m768.8m734.5m734.5m

Accounts Receivable

238.9m289.5m385.5m381.3m381.3m

Inventories

22.8m29.8m54.3m77.9m300.2m

Current Assets

1.6b1.9b2.1b2.3b2.3b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017Q1, 2017Q2, 2017Q1, 2019Q2, 2019

Cash

691.8m518.5m675.2m829.9m533.5m591.1m551.5m794.7m754.9m951.7m1.4b981.0m1.2b1.6b1.3b

Accounts Receivable

235.4m293.0m258.7m276.7m350.0m368.6m413.5m381.6m402.5m372.5m383.0m368.0m372.0m400.0m395.0m

Inventories

159.9m164.2m177.5m199.3m205.2m223.6m233.8m312.2m287.9m311.4m327.0m299.0m309.0m350.0m362.0m

Current Assets

1.5b1.6b1.6b1.9b2.1b2.2b2.2b2.3b2.1b2.1b2.8b2.5b2.6b3.2b3.3b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

125.3m353.4m457.4m428.1m428.1m

Depreciation and Amortization

50.8m61.9m72.7m90.0m90.0m

Inventories

1.8m6.6m(11.0m)(1.2m)(29.7m)

Accounts Payable

2.4m(2.1m)46.3m(2.0m)(2.0m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q1, 2019Q2, 2019

Net Income

31.4m60.0m46.6m93.5m136.7m102.2m115.6m116.9m87.2m116.4m348.0m197.0m397.0m

Depreciation and Amortization

30.0m65.0m

Inventories

177.5m199.3m205.2m223.6m233.8m312.2m287.9m311.4m299.0m(17.0m)(28.0m)

Accounts Payable

91.5m96.1m106.7m107.9m123.4m134.1m154.7m250.7m142.0m2.0m1.0m
USDY, 2018

EV/EBIT

104.8 x

EV/CFO

84.8 x

Financial Leverage

1.7 x
Show all financial metrics
Report incorrect company information

Illumina Online and Social Media Presence

Embed Graph
Report incorrect company information

Illumina News and Updates

Global Bioinformatics Technologies and Markets 2016-2022 with 3rd Millennium, Biomatters, Compugen, DNASTAR, and Illumina Dominating

DUBLIN, Oct. 23, 2018 /PRNewswire/ -- The "Bioinformatics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The scope of the study encompasses the global bioinformatics market based on geography, category and application. It provides a detailed...

NGS (Next Generation Sequencing) Global Market 2018-2025: Illumina, BGI, QIAGEN N. V, PerkinElmer

Wiseguyreports.Com Publish New Market Research Report On -“NGS (Next Generation Sequencing) Market - Global Industry Analysis, Size, Share, Trends, Growth and Forecast 2018 - 2025” Posted via Industry Today. Follow us on Twitter @IndustryToday

Global Cancer Genome Sequencing Market report provides data on the technological advancements, statistics for key segment and revenue, business segmentation, financial overview of the players such as Beckman Coulter Genomics, Illumina, SeqWright

Cancer genome sequencing market report includes a vast amount of data on recent discoveries and technology expansions detected in the market, investigating the impact of market intrusions on future development of the market. Posted via Industry Today. Follow us on Twitter @IndustryToday

Biochip 2018 Global Market Key Players – Abbott, Agilent Technologies, Illumina, PerkinElmer, Thermo Fisher Scientific – Analysis and Forecast to 2022

WiseGuyRerports.com Presents “Global Biochip Market 2017-2021” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday

Breast Cancer Liquid Biopsy Global Market Top Key Players – QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories (US), Myriad Genetics (US), Menarini Silicon Biosystems (Italy), Illumina (US)and Forecast to 2022

Breast Cancer Liquid Biopsy market size to maintain the average annual growth rate of 23.12% from 77.9 million $ in 2014 to 145.4 million $ in 2017, Posted via Industry Today. Follow us on Twitter @IndustryToday

GenomOncology Adds Jonathan Seaton, Former SVP Corporate & Business Development at Illumina, to its Board of Directors

CLEVELAND, Sept. 25, 2018 /PRNewswire/ -- GenomOncology LLC, a leading provider of end-to-end precision medicine solutions in oncology, has added Jonathan Seaton most recently Senior Vice President for Corporate & Business Development at Illumina to its Board of Directors. In addition to...
Show more
Report incorrect company information

Illumina Company Life and Culture

Report incorrect company information